tiprankstipranks
Blurbs

BioMarin Pharmaceutical (BMRN) Gets a Buy Rating from Robert W. Baird

In a report issued on February 24, Joel Beatty from Robert W. Baird maintained a Buy rating on BioMarin Pharmaceutical (BMRNResearch Report), with a price target of $112.00. The company’s shares closed last Friday at $78.00.

According to TipRanks.com, Beatty is a 2-star analyst with an average return of 1.0% and a 42.4% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and Syndax Pharmaceuticals.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $113.23, which is a 46.6% upside from current levels. In a report issued on February 24, Truist Financial also reiterated a Buy rating on the stock with a $135.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BioMarin Pharmaceutical’s market cap is currently $14.35B and has a P/E ratio of -222.48.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed